,0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16
0,분기,2019q1,2019q2,2019q3,2019q4,2020q1,2020q2,2020q3,2020q4,2021q1,2021q2,2021q3,2021q4,2022q1,2022q2,2022q3,2022q4
1,N/C/A,1743/59/29,2413/69/30,2167/58/29,3194/70/27,2373/53/26,2476/70/30,2942/59/29,3584/86/30,2619/69/30,2289/74/31,1969/64/27,3110/76/27,2454/70/27,3140/75/28,2904/70/31,3299/70/29
2,1,연구개발비,연구개발비,건강기능식품,자가면역질환,건강기능식품,건강기능식품,건강기능식품,건강기능식품,건강기능식품,건강기능식품,조합단백질,건강기능식품,기술이전계약,연구개발비,건강기능식품,건강기능식품
3,2,암조기진단,건강기능식품,연구개발비,연구개발비,체외진단기기,관절염치료,줄기세포치료,면역세포치료,줄기세포치료제,정밀화학기술,신약후보물질,세포치료개발,비소세포폐암,건강기능식품,연구개발비,아토피피부염
4,3,콜옵션행사,기술이전계약,자가면역질환,면역세포치료,줄기세포치료,품목허가취소,개발전문기업,자가면역질환,줄기세포치료,진단키트개발,긴급사용승인,효소바이오소재,자가면역질환,약물전달시스템,비소세포폐암,연구개발비
5,4,기존치료대비,자가면역질환,류마티스관절염,건강기능식품,체외진단시장,골관절염,회전근개파열,약물전달시스템,치료전문기업,화학기술기반,원료의약제조,국가출하승인,체외진단키트,경피약물전달,위식도역류,임상상진행
6,5,건강기능식품,중항체플랫폼,면역질환치료,보툴리눔톡신제재,비소세포폐암,코로나바이러스감염,퇴행관절염,류마티스관절염,골관절염,바이오신약개발,연구개발비,인체조직이식재,중항체플랫폼,골관절염,공장정기보수,편대숙주질환
